Viridian Therapeutics, Inc. (VRDN)
24.18
+0.16
(+0.67%)
USD |
NASDAQ |
Aug 25, 16:00
24.18
0.00 (0.00%)
After-Hours: 19:59
Viridian Therapeutics Shareholders Equity (Quarterly) : 662.10M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 662.10M |
| March 31, 2026 | 636.01M |
| December 31, 2025 | 722.17M |
| September 30, 2025 | 502.97M |
| June 30, 2025 | 515.17M |
| March 31, 2025 | 604.47M |
| December 31, 2024 | 671.64M |
| September 30, 2024 | 707.50M |
| June 30, 2024 | 529.34M |
| March 31, 2024 | 582.53M |
| December 31, 2023 | 442.02M |
| September 30, 2023 | 283.58M |
| June 30, 2023 | 315.86M |
| March 31, 2023 | 350.55M |
| December 31, 2022 | 395.06M |
| September 30, 2022 | 409.01M |
| June 30, 2022 | 141.90M |
| March 31, 2022 | 166.64M |
| December 31, 2021 | 187.72M |
| September 30, 2021 | 204.59M |
| June 30, 2021 | 98.91M |
| March 31, 2021 | 106.00M |
| December 31, 2020 | 120.04M |
| September 30, 2020 | 21.04M |
| June 30, 2020 | 21.17M |
| Date | Value |
|---|---|
| March 31, 2020 | 27.00M |
| December 31, 2019 | 15.75M |
| September 30, 2019 | 23.17M |
| June 30, 2019 | 33.44M |
| March 31, 2019 | 40.96M |
| December 31, 2018 | 51.34M |
| September 30, 2018 | 60.72M |
| June 30, 2018 | 67.67M |
| March 31, 2018 | 72.71M |
| December 31, 2017 | 38.51M |
| September 30, 2017 | 38.98M |
| June 30, 2017 | 41.34M |
| March 31, 2017 | 47.99M |
| December 31, 2016 | 15.06M |
| September 30, 2016 | 4.686M |
| June 30, 2016 | 6.437M |
| March 31, 2016 | 8.339M |
| December 31, 2015 | 10.41M |
| September 30, 2015 | 12.63M |
| June 30, 2015 | 10.94M |
| March 31, 2015 | 13.15M |
| December 31, 2014 | 5.991M |
| September 30, 2014 | 7.530M |
| June 30, 2014 | 8.463M |
| March 31, 2014 |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.307B |
| Alnylam Pharmaceuticals, Inc. | 1.354B |
| Anika Therapeutics, Inc. | 137.28M |
| Savara, Inc. | 143.66M |
| Vericel Corp. | 370.04M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 1.097B |
| Total Liabilities (Quarterly) | 435.14M |
| Debt to Equity Ratio | 0.3668 |
| Current Ratio | 16.95 |
| Net Debt Paydown Yield | -2.11% |